Tag Archives: AP26113

CEO Interview: Harvey Berger, Ariad Pharmaceuticals

Eight months into the launch of its first approved drug – Iclusig (ponatinib), a small molecule therapy indicated for two rare forms of leukemia – Ariad Pharmaceuticals’ principal founder and CEO Harvey Berger says doing it all, from discovery to global commercialization, is the company’s path to sustainability and the way to take on Big […]
Posted in Biotech, Europe, Gene therapy, Global, leadership, Market Access, Marketing, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta